Trials / Completed
CompletedNCT04312659
A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
A Multi-Center Registry Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Johnson & Johnson (China) Investment Ltd. · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to record the use of Infliximab (IFX) in the treatment of Chinese children with Crohn's disease (CD) in routine clinical practice and to summarize the clinical efficacy and safety of IFX in the treatment of pediatric CD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Infliximab | Participants will be observed who were treated with Infliximab. |
Timeline
- Start date
- 2020-07-15
- Primary completion
- 2023-09-12
- Completion
- 2023-09-12
- First posted
- 2020-03-18
- Last updated
- 2025-04-27
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04312659. Inclusion in this directory is not an endorsement.